Physician profile
Michael A Farber
NPI 1154301679
$6,562.80
in general payments reported to CMS, 2019-2025
38 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $292 · 2021: $670 · 2022: $1,243 · 2023: $1,356 · 2024: $1,190 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,741 · Education: $6.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,740.67 |
| Education | $6.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $964.81 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $901.43 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $785.79 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $739.32 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Gilead Sciences, INC. | $364.02 | 2019-2024 | |
| Qol Medical, LLC | $282.64 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $262.92 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $258.82 | 2024-2025 | Voquezna |
| Genzyme Corporation | $215.48 | 2022-2025 | |
| Ardelyx, INC. | $185.22 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $175.68 | 2020-2022 | |
| Pfizer INC. | $165.65 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $158.03 | 2019-2024 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $124.26 | 2020-2024 | |
| Lilly USA, LLC | $124.00 | 2024-2025 | Omvoh |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $102.48 | 2020-2025 | Sutab, Suflave |
| Allergan, INC. | $79.59 | 2019 | |
| Madrigal Pharmaceuticals | $77.40 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $74.41 | 2023-2025 | Dupixent |
| Celltrion USA INC. | $69.88 | 2024-2025 | Vegzelma |
| Boston Scientific Corporation | $58.29 | 2019 | |
| Ferring Pharmaceuticals INC. | $56.73 | 2019 | |
| Daiichi Sankyo INC. | $38.81 | 2023 | Injectafer |
| Merck Sharp & Dohme LLC | $27.86 | 2021 | |
| Aimmune Therapeutics, INC. | $24.20 | 2025 | Zenpep |
| Rhythm Pharmaceuticals, INC. | $23.32 | 2023 | Imcivree |
| W. L. Gore & Associates, INC. | $23.12 | 2023 | Gore Cardioform Septal Occluder |
| Astrazeneca Pharmaceuticals LP | $23.09 | 2023 | Wainua |
| Novo Nordisk INC | $21.04 | 2025 | Wegovy |
| Amgen INC. | $20.96 | 2023 | Avsola |
| Vivus LLC | $18.22 | 2019 | |
| Sandoz INC. | $17.86 | 2023 | Hyrimoz |
| Micro-Tech Endoscopy USA, INC. | $17.60 | 2023 | Lesionhunter |
| Ucb, INC. | $17.49 | 2019 | |
| Fresenius Kabi USA, LLC | $16.97 | 2023 | |
| Organon LLC | $16.82 | 2025 | Hadlima |
| Ipsen Biopharmaceuticals, INC | $16.18 | 2025 | Iqirvo |
| Lexicon Pharmaceuticals, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Farber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.